SCHEMBL29566644

SCHEMBL29566644

CNC(=O)c1cc(Cl)cc(Oc2cc(-c3c(C)cccc3C)nc(NS(=O)(=O)c3cnn(C)c3)n2)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 4/20 0.39
▸ KDR P35968 4/20 0.39
▸ EGFR P00533 2/20 0.39
▸ F2 P00734 1/20 0.38
▸ F10 P00742 1/20 0.38
▸ CYP3A4 P08684 3/20 0.36
▸ AURKA O14965 2/20 0.36
▸ AURKB Q96GD4 2/20 0.36
▸ GRM5 P41594 2/20 0.35
▸ FGFR2 P21802 2/20 0.35
▸ FGFR4 P22455 2/20 0.35
▸ FGFR3 P22607 2/20 0.35
▸ GPR119 Q8TDV5 3/20 0.35
▸ ADCY10 Q96PN6 1/20 0.34
▸ NR1H2 P55055 1/20 0.34
▸ NR1H3 Q13133 1/20 0.34
▸ CREBBP Q92793 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ FLT3 P36888 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26874925 1.00 FGFR1 (0.39) FGFR1KDREGFRF2F10
SCHEMBL26810134 0.92 PTGDR2 (0.41) FGFR1KDREGFRCYP3A4GPR119
SCHEMBL24310791 0.92 EGFR (0.38) FGFR1KDREGFRF2F10
SCHEMBL29567535 0.92 EGFR (0.38) FGFR1KDREGFRF2F10
SCHEMBL29567200 0.91 F10 (0.43) FGFR1KDREGFRF2F10
SCHEMBL24310795 0.91 F10 (0.43) FGFR1KDREGFRF2F10
SCHEMBL26810137 0.91 NR1H2 (0.39) FGFR1KDREGFRCYP3A4AURKA
SCHEMBL26810272 0.90 EGFR (0.38) FGFR1KDREGFRF2F10
SCHEMBL26810132 0.90 EGFR (0.36) FGFR1KDREGFRCYP3A4AURKA
SCHEMBL26810139 0.90 CCR2 (0.37) FGFR1KDREGFRCYP3A4GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback